Literature DB >> 10623817

Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma.

A Sica1, A Saccani, B Bottazzi, S Bernasconi, P Allavena, B Gaetano, F Fei, G LaRosa, C Scotton, F Balkwill, A Mantovani.   

Abstract

Monocyte chemotactic protein-1 (MCP-1, CCL2) is an important determinant of macrophage infiltration in tumors, ovarian carcinoma in particular. MCP-1 binds the chemokine receptor CCR2. Recent results indicate that proinflammatory and anti-inflammatory signals regulate chemokine receptor expression in monocytes. The present study was designed to investigate the expression of CCR2 in tumor-associated macrophages (TAM) from ovarian cancer patients. TAM isolated from ascitic or solid ovarian carcinoma displayed defective CCR2 mRNA (Northern blot and PCR) and surface expression and did not migrate in response to MCP-1. The defect was selective for CCR2 in that CCR1 and CCR5 were expressed normally in TAM. CCR2 gene expression and chemotactic response to MCP-1 were decreased to a lesser extent in blood monocytes from cancer patients. CCR2 mRNA levels and the chemotactic response to MCP-1 were drastically reduced in fresh monocytes cultured in the presence of tumor ascites from cancer patients. Ab against TNF-alpha restored the CCR2 mRNA level in monocytes cultured in the presence of ascitic fluid. The finding of defective CCR2 expression in TAM, largely dependent on local TNF production, is consistent with previous in vitro data on down-regulation of chemokine receptors by proinflammatory molecules. Receptor inhibition may serve as a mechanism to arrest and retain recruited macrophages and to prevent chemokine scavenging by mononuclear phagocytes at sites of inflammation and tumor growth. In the presence of advanced tumors or chronic inflammation, systemic down-regulation of receptor expression by proinflammatory molecules leaking in the systemic circulation may account for defective chemotaxis and a defective capacity to mount inflammatory responses associated with advanced neoplasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623817     DOI: 10.4049/jimmunol.164.2.733

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  CD192 gene variant and susceptibility to cervical cancer: a meta analysis.

Authors:  Yuying Chen; Xinli Liu; Min Chen; Jian Shen; Yanqi Lu; Lei Yu; Shouying Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB.

Authors:  Simon Hallam; Monica Escorcio-Correia; Robin Soper; Anne Schultheiss; Thorsten Hagemann
Journal:  J Pathol       Date:  2009-10       Impact factor: 7.996

Review 3.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions.

Authors:  Subhra K Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Immunopathol       Date:  2013-05-09       Impact factor: 9.623

4.  Biomaterial Scaffolds as Pre-metastatic Niche Mimics Systemically Alter the Primary Tumor and Tumor Microenvironment.

Authors:  Brian A Aguado; Rachel M Hartfield; Grace G Bushnell; Joseph T Decker; Samira M Azarin; Dhaval Nanavati; Matthew J Schipma; Shreyas S Rao; Robert S Oakes; Yining Zhang; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Adv Healthc Mater       Date:  2018-03-09       Impact factor: 9.933

5.  Expression pattern and action analysis of genes associated with the responses to chemical stimuli during rat liver regeneration.

Authors:  Shao-Wei Qin; Li-Feng Zhao; Xiao-Guang Chen; Cun-Shuan Xu
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

6.  Therapeutic potential of adipose-derived stem cells and macrophages for ischemic skeletal muscle repair.

Authors:  Viktoriya Rybalko; Pei-Ling Hsieh; Laura M Ricles; Eunna Chung; Roger P Farrar; Laura J Suggs
Journal:  Regen Med       Date:  2017-02-16       Impact factor: 3.806

7.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation.

Authors:  Faraz Bishehsari; Lijuan Zhang; Usman Barlass; Nailliw Z Preite; Sanja Turturro; Matthew S Najor; Brandon B Shetuni; Janet P Zayas; Mahboobeh Mahdavinia; Abde M Abukhdeir; Ali Keshavarzian
Journal:  Int J Cancer       Date:  2018-08-09       Impact factor: 7.396

Review 9.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  CCL25 Signaling in the Tumor Microenvironment.

Authors:  Hina Mir; Shailesh Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.